Pancreatic Cancer Research

ResearcherChina Pharmaceutical UniversityActive in the last 2 years

Yang Zhou

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5199-156X; OpenAlex author ID A5050909388. Sources: OpenAlex.

Their work

Papers
4 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
6
Papers, trials and grants by year

2019: 2 papers · 2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: 1 paper

Papers 4

  1. A comparative analysis and survival analysis of open versus minimally invasive radical antegrade modular pancreatosplenectomy for pancreatic cancer: a systemat… Co-author DOI 10.3389/fonc.2024.1513520↗
  2. HEATR1 deficiency promotes pancreatic cancer proliferation and gemcitabine resistance by up-regulating Nrf2 signaling. Co-author DOI 10.1016/j.redox.2019.101390↗
  3. Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway. First author DOI 10.1016/j.redox.2019.101131↗
  4. ROCK2 Confers Acquired Gemcitabine Resistance in Pancreatic Cancer Cells by Upregulating Transcription Factor ZEB1. Co-author DOI 10.2139/ssrn.3439545↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Fei Xue · 1 shared paper, 2024 · strength 0.46
  2. Yunjiang Zhou · 3 shared papers, 2019–2020 · strength 0.31
  3. Rong Hu · 3 shared papers, 2019–2020 · strength 0.31
  4. Rui Wang · 2 shared papers, 2019–2020 · strength 0.21
  5. Tao Li · 1 shared paper, 2019 · strength 0.10
  6. Rui Wang · 1 shared paper, 2019 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.